| Gene symbol | TNFRSF17 | Synonyms | BCM, BCMA, CD269, TNFRSF13A | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p13.13 | dbXrefs | |
| Description | TNF receptor superfamily member 17 | ||||
| GTO ID | GTC3442 |
| Trial ID | NCT05860036 |
| Disease | Multiple Myeloma |
| Altered gene | BCMA |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | BCMA CAR-T cells |
| Co-treatment | Bortezomib, Lenalidomide and Dexamethasone |
| Phase | Phase2 |
| Recruitment status | Recruiting |
| Title | A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by BCMA CAR-T Therapy in Transplant-Ineligible Patients With New-diagnosed Multiple Myeloma |
| Year | 2023 |
| Country | China |
| Company sponsor | Institute of Hematology & Blood Diseases Hospital |
| Other ID(s) | CAREMM-001 |
| Cohort 1 | |||||||||||
|
|||||||||||